Signal
Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from Celgene.
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-30 14:38 UTCUpdated 2026-04-30 18:28 UTC
rss
fierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Coverage centers on: Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.
Score total
0.82
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.
Fierce Pharma (All) · fiercepharma.com · 2026-04-30 18:28 UTC
Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from Celgene.
Fierce Biotech · fiercebiotech.com · 2026-04-30 14:38 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- Fierce Biotech (1)
Top origin domains (this list)
- fiercepharma.com (1)
- fiercebiotech.com (1)